Lesley Stolz, PhD, is currently the EVP and Chief Business Officer at Annexon Biosciences, a clinical stage company focused on neurodegenerative and autoimmune disorders that have synapse loss as their primary mode of action. Prior to Annexon, she spent 5 years at Johnson & Johnson Innovation negotiating transactions and running the West Coast JLABS business. She has over 20 years of business and corporate development experience working for companies that have been both technology platform and therapeutics focused. She has also held executive positions with BioTime, Inc., Sutro Biopharma, Inc., and Sunesis Pharmaceuticals where she was responsible for corporate strategy, fundraising and all aspects of partnering. Earlier in her career, she served as Senior Director, Business Development for Aerovance, Inc., GPC Biotech AG in Munich, Germany, and several other companies. Dr. Stolz received her Ph.D. in chemistry, and conducted postdoctoral research at Harvard Medical School’s Department of Biochemistry and Molecular Pharmacology.